Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.52B 4.12B 3.79B 3.45B 6.48B 419B 6.81B 46.18B 18.35B 229B 16.96B 16.61B 718B P/E 2026 *
-70.9x
P/E 2027 * -508x
Enterprise Value 4.28B 3.9B 3.59B 3.27B 6.13B 397B 6.45B 43.75B 17.39B 217B 16.07B 15.73B 680B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.4x
Free-Float
98.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week-3.82%
Current month+4.84%
1 month+10.26%
3 months+7.46%
6 months+101.37%
Current year+71.98%
1 week 27.15
Extreme 27.1501
29.8
1 month 23.82
Extreme 23.82
32.21
Current year 12
Extreme 12
32.21
1 year 12
Extreme 12
32.21
3 years 2.28
Extreme 2.28
32.21
5 years 2.28
Extreme 2.28
32.21
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Exercice

Chairperson

35,643 0.0223%
29/10/26 Exercice

Chairperson

35,643 0.0223%
26/10/26 Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-3.82%+50.08%+561.85% 4.52B
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.87B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.28%-1.48%+34.77%+218.67% 40B
Weighted average by Cap. -1.47%-1.87%+32.03%+159.73%

Financials

2026 *2027 *
Net sales 307M 280M 258M 234M 440M 28.42B 462M 3.14B 1.25B 15.53B 1.15B 1.13B 48.72B 374M 341M 314M 286M 536M 34.66B 563M 3.82B 1.52B 18.93B 1.4B 1.37B 59.42B
Net income -63.64M -57.96M -53.41M -48.58M -91.14M -5.89B -95.79M -650M -258M -3.22B -239M -234M -10.1B -9.66M -8.79M -8.1M -7.37M -13.83M -894M -14.53M -98.63M -39.2M -488M -36.23M -35.46M -1.53B
Net Debt -238M -216M -199M -181M -340M -22.01B -358M -2.43B -965M -12.02B -892M -873M -37.72B -266M -243M -224M -203M -382M -24.68B -401M -2.72B -1.08B -13.48B -1B -979M -42.3B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
20/11/26 $27.93 -0.43% 2,483,169
19/11/26 $28.05 -1.44% 1,894,447
18/11/26 $28.46 -0.11% 2,209,991
17/11/26 $28.49 +2.22% 1,938,192
16/11/26 $27.87 -4.03% 2,657,890
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
27.93USD
Average target price
33.86USD
Spread / Average Target
+21.22%
  1. Stock Market
  2. Stocks
  3. ADPT Stock